We strive to offer our customers best in class solutions for post-transplant monitoring to improve the quality of life for transplant recipients. Our new products enable for a particularly sensitive chimerism monitoring and for a non-invasive solid organ health monitoring. Both products will facilitate earlier detection of the disease and allow the initiation of timely therapeutic intervention.

JETA Molecular is proud to introduce new assays designed for monitoring of the genomic loss of the mismatched HLA haplotype (HLA LOH) following haploidentical HSCT. This event occurs in an average of 33% of post-HSCT patients and is sufficient to allow relapse of leukemia. The HLA TRACE™ assays represent a sensitive solution for the detection of LOH and may form the basis for optimising patient-tailored therapy.

JETA Molecular presented both its well-established products as well as novel strategies in DNA chimerism monitoring during the 33th EFI congress in Lisbon, May 8-11, and during the 2019 American Transplant Congress in Boston, June 1-5. You will also be able to meet our representatives at the SFHI meeting in Nancy, September 19-20, and at the ASHI 45th Annual Meeting in Pittsburgh, September 23-27. Feel free to come by!